Journal ArticleDOI
The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis.
Tien Wong,Usha Chakravarthy,Ronald Klein,Paul Mitchell,Gergana Zlateva,Ronald Buggage,Kyle Fahrbach,Corey Probst,Isabella Sledge +8 more
TLDR
A doubling of the visual angle of presenting VA may be expected to occur in the year after initial presentation in eyes with untreated neovascular AMD, and the diversity of reporting formats, paucity of long-term natural history data, and heterogeneity among the reported clinical studies impose limits to the clear understanding ofLong-term prognosis for visual function in neov vascular AMD.Citations
More filters
Journal ArticleDOI
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wan-Ling Wong,Xinyi Su,Xiang Li,Chui Ming Gemmy Cheung,Ronald Klein,Ching-Yu Cheng,Tien Yin Wong +6 more
TL;DR: In this article, the authors did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013, using retinal photographs and standardised grading classifications.
Journal ArticleDOI
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
TL;DR: A 2-year phase III trial designated ANCHOR as discussed by the authors compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV.
Journal ArticleDOI
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
TL;DR: Assessing long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration patients found one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes.
Journal ArticleDOI
Mechanisms of age-related macular degeneration
TL;DR: Insight is provided into the critical effector pathways mediating each form of the disease and a recurring theme that spans most aspects of AMD pathogenesis is defective immune modulation in the classically immune-privileged ocular haven.
Journal ArticleDOI
Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis
Usha Chakravarthy,Tien Yin Wong,Tien Yin Wong,Astrid E. Fletcher,Elisabeth Piault,Christopher M. Evans,Gergana Zlateva,Ronald Buggage,Andreas M. Pleil,Paul Mitchell +9 more
TL;DR: Increasing age, current cigarette smoking, previous cataract surgery, and a family history of AMD showed strong and consistent associations with late AMD.
References
More filters
Journal ArticleDOI
Assessing the quality of reports of randomized clinical trials : is blinding necessary?
Alejandro R. Jadad,R. A. Moore,Dawn Carroll,C. Jenkinson,David Reynolds,David J. Gavaghan,Henry J McQuay +6 more
TL;DR: An instrument to assess the quality of reports of randomized clinical trials (RCTs) in pain research is described and its use to determine the effect of rater blinding on the assessments of quality is described.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Prevalence of age-related macular degeneration in the United States.
David S. Friedman,O'Colmain Bj,Beatriz Munoz,Sandra C. Tomany,Catherine A. McCarty,de Jong Pt,de Jong Pt,de Jong Pt,Barbara Nemesure,Paul Mitchell,Paul Mitchell,John H. Kempen +11 more
TL;DR: In this article, the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender was estimated.
Journal ArticleDOI
Pegaptanib for Neovascular Age-Related Macular Degeneration
TL;DR: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.
Journal ArticleDOI
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
TL;DR: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration (AMD).
Related Papers (5)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more